TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06372782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Skinboosters Vital Lidocaine
Description: Each subject will receive treatment on Day 1 with Restylane Skinboosters Vital Lidocaine in one hand and Restylane Vital in the opposite hand, as randomly assigned.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Skinboosters Vital Lidocaine
Description: Each subject will receive treatment on Day 1 with Restylane Skinboosters Vital Lidocaine in one hand and Restylane Vital in the opposite hand, as randomly assigned.
Study: NCT06372782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Vital
Description: Each subject will receive treatment on Day 1 with Restylane Vital in one hand and the experimental device in the opposite hand, as randomly assigned

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Vital
Description: Each subject will receive treatment on Day 1 with Restylane Vital in one hand and the experimental device in the opposite hand, as randomly assigned
Study: NCT06391775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Chemotherapy
Description: IV administration
Study: NCT05180474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
Description: GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
Study: NCT06018129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN3017
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN3017
Description: Subcutaneous injection
Study: NCT05718271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explicit instructions before extinction
Description: Shocks will no longer be administered during the next phase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explicit instructions before extinction
Description: Shocks will no longer be administered during the next phase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explicit instructions after extinction
Description: Tomorrow no shocks will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explicit instructions after extinction
Description: Tomorrow no shocks will be administered.
Study: NCT05148754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsulfavirine
Description: Elsulfavirin 200 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsulfavirine
Description: Elsulfavirin 200 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsulfavirine
Description: Elsulfavirin 200 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsulfavirine
Description: Elsulfavirin 200 mg tablets.
Study: NCT05699798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative Treatment (CT)
Description: Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument-assisted Soft Tissue Mobilization (IASTM)
Description: IASTM was performed only on the neck and upper back muscles on the aching side using the sweep technique on the origo and insertion lines. A total of 6 sessions were applied, two sessions per week for 3 weeks.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: ESWT therapy was applied on the muscle with active trigger point, at 1.5-2.0 bar pressure, at 10 Hz frequency, 2000 beats in each session, twice a week, in total 6 sessions.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.
Study: NCT06466512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Midwifery-embodied care
Description: The midwife will provide ANC, delivery and PNC. The Community Healthcare Provider, Health Assistants will act as auxillary staff. Local transports will be integrated into the system. Coordination committee will see through that the interventions are carried out properly.
Study: NCT04923022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegan Diet
Description: Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Individuals in the therapeutic exercise group will perform therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.
Study: NCT05445557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RZL-012
Description: small synthetic molecule for submental fat reduction
Study: NCT04867603

Intervention type: DRUG
Intervention: [Ga-68]PSMA
Description: The injectable activity will be a maximum of 210 MBq (6.0 mCi) \[Ga-68\]PSMA at the time of injection and is administered to subjects by intravenous injection.

Intervention type: DEVICE
Intervention: PET/CT imaging
Description: PET/CT imaging procedure
Study: NCT05445557

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06179667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: It is aimed to develop the mobile application to address the problems and training needs of informal caregivers regarding the caregiving process. In this context, in order to determine the needs of caregivers, face-to-face in-depth interviews will be held with caregivers using the Semi-Structured Questionnaire for Qualitative Interviews at the University of Health Sciences GTRH Geriatrics Department. The content of the mobile application will be created according to the topics determined as a result of qualitative research. Technical development of the application will be carried out by the web application designer.
Study: NCT02659124

Intervention type: DEVICE
Group type: OTHER
Intervention: AmnioFix plus Standard of Care
Description: Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care
Description: Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
Study: NCT06340815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Proton Therapy System (ProBeam)
Description: All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.~And long-term follow-up report will be submitted for future post market evaluation when requested by NMPA.
Study: NCT04932018

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Virtual Community of Support
Description: The 6-month virtual community will consist of self-directed learning modules that will vary in content from worker and family relationships, collaboration and skill acquisition to self-care habits; problem-solving; monthly sessions will include a positive psychology exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Community of Support
Description: The 6-month virtual community will consist of self-directed learning modules that will vary in content from worker and family relationships, collaboration and skill acquisition to self-care habits; problem-solving; monthly sessions will include a positive psychology exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentorship Incubator
Description: The 6-month incubator intervention will consist of monthly interactive time with an assigned study facilitator/farmer mentor.
Study: NCT06357598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, neoadjuvant therapy : 2-4 cycles; Adjuvant therapy: 16cycles at most.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)
Description: Pemetrexed: 500 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin or Cisplatin
Description: Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 of each 21-day cycle for 2-4 cycles.~Cisplatin: 75 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.
Study: NCT05567692

Intervention type: DIAGNOSTIC_TEST
Intervention: OGTT
Description: Oral Glucose Tolerance Test

Intervention type: OTHER
Intervention: HbA1c
Description: HbA1c measurement

Intervention type: OTHER
Intervention: Questionnaire
Description: Follow-up questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Follow-up questionnaire
Study: NCT06392503

Intervention type: DIAGNOSTIC_TEST
Intervention: different diagnostic models
Description: the patients were screened by different diagnostic models

Intervention type: DIAGNOSTIC_TEST
Intervention: different diagnostic models
Description: the patients were screened by different diagnostic models
Study: NCT05248191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capsule fecal microbiota material (cap-FMT)
Description: Cap-FMT consists of Lyophilized FMT administered at 5 x 10\^11 bacteria per capsule daily for five days, for a total dose of 2.5 x 10\^12 bacteria.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopic fecal microbiota material (colo-FMT)
Description: Colo-FMT consists of rehydrated Lyophilized FMT material administered as a single dose of 2.5 x 10\^12 bacteria as liquid.
Study: NCT05789446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building a Strong Identity and Coping Skills
Description: Psychoeducational program to teach children coping skills, healthy identity development, and collective social action
Study: NCT05047510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-GPC3-IRDye800CW
Description: Drug Injection: Anti-GPC3-IRDye800CW
Study: NCT06385223

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Beam F3 targeted accelerated iTBS
Description: Magpro X100, Axilium Cobot, Localite camera

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized connectome-guided accelerated iTBS
Description: Magpro X100, Axilium Cobot, Localite camera
Study: NCT05700045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: each side dexmedetomidine 0.5ug/kg TAP block
Study: NCT06443710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium [99mTc]-H7ND injection
Description: Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
Study: NCT05377658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: 10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 260mg/m\^2 via intravenous infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.
Study: NCT06514664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using Probiotic Toothpaste
Description: Scaling and root planing (Phase 1 = non-surgical periodontal treatment) are performed in all patient groups.~Depending on the study groups, regular or probiotic toothpaste will be used. Toothpaste is instructed to be used twice a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using Probiotic Toothpaste
Description: Scaling and root planing (Phase 1 = non-surgical periodontal treatment) are performed in all patient groups.~Depending on the study groups, regular or probiotic toothpaste will be used. Toothpaste is instructed to be used twice a day
Study: NCT06170346

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Antioxidants
Description: 30 drops of topical antioxidants (Gluconolactone 4%, Hyaluronic acid 0,01%, Allantoin 0,1%, Ferulic acid 3%, Acetyl heptapeptide 0,001%, Silver vine extract 1%, Ectoine 0,01%, Hydroxyectoine 0,01%, and vehicle) will be applied on tested area on each participant for four consecutive days.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 30 drops of topical vehicle (Aqua, Dipropylene glycol, Hydroxypropyl cyclodextrin, Polydextrose, 1,2-hexanediol, Butylene glycol, Propanediol, Caprylhydroxamic acid, Ethylhexylglycerin, Xanthan gum, Benzyl alcohol, Glyceryl caprylate, and Benzoic acid) will be applied on tested area on each participant for four consecutive days.
Study: NCT06446752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero
Description: Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
Study: NCT06321198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iMSC
Description: Subjects will receive 4 or more times of iMSC injection
Study: NCT06500858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive a welcome package with exercise equipment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in virtual-exercise sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive access to optional drop-in classes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive monthly newsletters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive access to online fitness buddy matching program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participate in a walking program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05536752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QA102/Placebo
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QA102
Description: Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study: NCT05843552

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, this is an observational study

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, this is an observational study

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, this is an observational study
Study: NCT04834414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cold Stored Platelets
Description: Platelets stored at 1-6 degree Celsius

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Room Temperature Platelets
Description: Platelets stored at 20-24 degrees Celsius
Study: NCT06071429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold
Description: CLTI patients treated with MAGNITUDE BRS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Description: CLTI patients treated with PTA
Study: NCT06099470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time synchronized telerehabilitation program (STP).
Description: patient education, core stabilization exercises, strengthening exercises, stretching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-recording non-synchronized telerehabilitation program (NSTP)
Description: Pre-recording non-synchronized telerehabilitation program (NSTP)

Intervention type: OTHER
Group type: OTHER
Intervention: Home non-supervised control group (HCG)
Description: Home non-supervised control group (HCG)
Study: NCT06424158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Massage therapy (MT) has been proven as an alternative non-opioid pain management intervention, particularly towards reducing pain, diminishing depression, improving immune function, and increasing alertness in the adult population. MT raises the temperature of local tissues, dilates capillaries, accelerates the circulation of blood and lymph, promotes the absorption of local tissue metabolism and mass inflammation, improves the nutritional supply of surrounding muscle groups, promotes their growth and development, and relieves pain.
Study: NCT05824039

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea infusion
Description: Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.
Study: NCT05459324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD Study Electrode
Description: The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
Study: NCT05491954

Intervention type: DEVICE
Intervention: Dexcom G6
Description: Continuous glucose monitoring

Intervention type: DEVICE
Intervention: Dexcom G6
Description: Continuous glucose monitoring

Intervention type: DEVICE
Intervention: Dexcom G6
Description: Continuous glucose monitoring

Intervention type: DEVICE
Intervention: Dexcom G6
Description: Continuous glucose monitoring
Study: NCT05192551

Intervention type: OTHER
Intervention: Bowel-prep (Plenvu as experimental arm)
Description: In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine

Intervention type: OTHER
Intervention: Bowel-prep (Plenvu as experimental arm)
Description: In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine

Intervention type: OTHER
Intervention: Bowel-prep (Plenvu as experimental arm)
Description: In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine

Intervention type: OTHER
Intervention: Bowel-prep (Plenvu as experimental arm)
Description: In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine
Study: NCT05328791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and mindfulness intervention
Description: Dietary intervention: Preparation and follow-up of diet program~Mindfulness intervention: Implementation of cognitive stress reduction program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and mindfulness intervention
Description: Dietary intervention: Preparation and follow-up of diet program~Mindfulness intervention: Implementation of cognitive stress reduction program
Study: NCT05030974

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: SARS-CoV-2 vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: SARS-CoV-2 vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: SARS-CoV-2 vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: SARS-CoV-2 vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.COV2.S vaccine
Description: SARS-CoV-2 vaccination
Study: NCT05000177

Intervention type: OTHER
Group type: OTHER
Intervention: 30-minute computer typing task
Description: The subject sits in front of a computer screen and perform computer typing tasks for 30 minutes. The same computer table and chair were used for all subjects. The height of the table and screen, and the distance of the keyboard from the subject were adjusted according to their familiar and comfortable position.

Intervention type: OTHER
Group type: OTHER
Intervention: 30-minute computer typing task
Description: The subject sits in front of a computer screen and perform computer typing tasks for 30 minutes. The same computer table and chair were used for all subjects. The height of the table and screen, and the distance of the keyboard from the subject were adjusted according to their familiar and comfortable position.

Intervention type: OTHER
Group type: OTHER
Intervention: 30-minute rest
Description: Rest for 30 minutes